Literature DB >> 5908975

Primary pulmonary hypertension with emphasis on its etiology and treatment.

O Storstein, L Efskind, C Müller, R Rokseth, S Sander.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1966        PMID： 5908975     DOI： 10.1111/j.0954-6820.1966.tb05449.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN： 0001-6101


× No keyword cloud information.
  12 in total

Review 1.  Anticoagulation in Pulmonary Arterial Hypertension.

Authors:  Jeffrey C Robinson; Steven C Pugliese; Daniel L Fox; David B Badesch
Journal:  Curr Hypertens Rep       Date:  2016-06       Impact factor: 5.369

2.  Where do we go from here? Reappraising the data on anticoagulation in pulmonary arterial hypertension.

Authors:  Meghan M Cirulis; John J Ryan
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

3.  Cardiopulmonary function in patients with pulmonary hypertension.

Authors:  N Gazetopoulos; N Salonikides; H Davies
Journal:  Br Heart J       Date:  1974-01

4.  Primary pulmonary hypertension: modern approaches to an old problem.

Authors:  S Fein; W Frishman
Journal:  Lung       Date:  1980       Impact factor: 2.584

Review 5.  Anticoagulant treatment in patients with pulmonary arterial hypertension associated with systemic sclerosis: More shadows than lights.

Authors:  Massimiliano Palazzini; Alessandra Manes; Enrico Gotti; Fabio Dardi; Andrea Rinaldi; Nazzareno Galiè
Journal:  J Scleroderma Relat Disord       Date:  2018-04-04

6.  Is Anticoagulation Beneficial in Pulmonary Arterial Hypertension?

Authors:  Muhammad Shahzeb Khan; Muhammad Shariq Usman; Tariq Jamal Siddiqi; Safi U Khan; M Hassan Murad; Farouk Mookadam; Vincent M Figueredo; Richard A Krasuski; Raymond L Benza; Jonathan D Rich
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2018-09

7.  KMA-Greenfield filter placement for chronic pulmonary hypertension.

Authors:  L J Greenfield; L A Scher; R C Elkins
Journal:  Ann Surg       Date:  1979-05       Impact factor: 12.969

Review 8.  Thrombosis, platelets, microparticles and PAH: more than a clot.

Authors:  Katie L Lannan; Richard P Phipps; R James White
Journal:  Drug Discov Today       Date:  2014-04-18       Impact factor: 7.851

9.  Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL).

Authors:  Ioana R Preston; Kari E Roberts; Dave P Miller; Ginny P Sen; Mona Selej; Wade W Benton; Nicholas S Hill; Harrison W Farber
Journal:  Circulation       Date:  2015-10-28       Impact factor: 29.690

10.  Pulmonary arterial hypertension patients display normal kinetics of clot formation using thrombelastography.

Authors:  Mengyun Lu; Kevin P Blaine; Ann Cullinane; Courtney Hall; Alina Dulau-Florea; Junfeng Sun; Herman F Chenwi; Grace M Graninger; Bonnie Harper; Keshia Thompson; Janell Krack; Christopher F Barnett; Samuel B Brusca; Jason M Elinoff; Michael A Solomon
Journal:  Pulm Circ       Date:  2021-06-24       Impact factor: 3.017
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.